Section 8
Chapter 7,510

Left ventricular dynamics in chronic congestive heart failure during treatment with etozolin a noninvasive study

Burdick, L.; Mangiaroti, R.; Pini, C.; Fasoli, A.

Current Therapeutic Research 48(1): 167-173


ISSN/ISBN: 0011-393X
Accession: 007509003

Download citation:  

Congestive heart failure is a lethal end stage of heart disease that has no satisfactory treatment. Present therapeutic regimens focus on improving impaired ventricular function in order to increase survival. Etozolin is a novel loop diuretic agent that possesses direct vasodilating properties and has proved to be effective in essential hypertension. We assessed left ventricular (LV) function in 15 patients in sinus rhythm with mild to moderate chronic heart failure using computer-assisted analysis of echocardiograms. Etozolin caused significant modifications both in systolic and diastolic LV function. LV cavity dimensions decreased, while there was a significant improvement in the ejection phase index the mean velocity of circumferential shortening after four weeks of treatment (P < 0.05). LV diastolic function likewise improved significantly; the duration of the rapid filling phase was shortened after 12 weeks (P < 0.05) and the rate of increase in LV dimensions improved after four weeks (P < 0.05). Blood urea nitrogen, serum creatinine, sodium and potassium concentrations, blood glucose, and lipids did not change significantly. There was a reduction in heart rate and diastolic blood pressure. No adverse side effects were noted. We conclude that etozolin is a useful agent in the treatment of congestive heart failure. By combining diuretic properties with a direct vasodilating activity, it may prove particularly effective in the long-term stabilization of these patients.

PDF emailed within 1 workday: $29.90